Calif.--(BUSINESS WIRE)--April 20, 2005--Arrowhead
Research Corporation (NASDAQ:ARWR) (NASDAQ:ARWRW)
announced today that its majority-owned subsidiary,
Insert Therapeutics, has released data demonstrating
effective anti-cancer results in animal studies of
its lead product, IT-101, against various cancers,
including pancreatic cancer, colon cancer, breast
cancer, lung cancer, and Ewing's Sarcoma, a cancer
primarily affecting children and young adults. In
the case of two of the cancers, total tumor remission
was achieved and the animals remained tumor free throughout
the length of the 90-day study. Phase I/II human safety
and efficacy trials are scheduled to begin at the
City of Hope Medical Center upon clearance of regulatory
requirements, expected later this year.
All animals with Ewing's Sarcoma and all animals with
non small-cell lung cancer, which represents approximately
80% of lung cancers, experienced total tumor remission
and remained tumor free throughout the duration of
the 90-day study. IT-101 takes advantage of the "leaky"
blood vessels of tumors to accumulate selectively
in the tumors. Once inside the tumor cell, its slow
release of the drug contributes to protracted anti-tumor
activities that are substantially more effective at
significantly lower doses.
"We are optimistic that
this product will finally effectively treat some of
the most difficult to treat cancers and provide a
better and safer treatment for cancer in general,"
said R. Bruce Stewart, President of Arrowhead Research.
IT-101 is a conjugate of Insert's
proprietary nano-engineered drug delivery vehicle,
Cyclosert(TM) and the anti-cancer drug, camptothecin.
Analogues of camptothecin, specifically irinotecan
and topotecan, have nearly $1 billion in annual reported
worldwide sales, despite the still serious side effects
of these medications. In the study, anti-tumor activity
in IT-101 treated animals was superior to irinotecan
treated animals in all tumor models tested.
Dr. Thomas Schluep, Chief Scientific
Officer at Insert Therapeutics presented the results
of the animal studies at the American Association
of Cancer Research Annual Meeting in Anaheim, Calif.
on April 17, 2005.
About Arrowhead Research Corporation
Arrowhead Research is a development-stage
nanotechnology company structured to bring together
a diverse and innovative mix of technologies, rights
to a broad suite of intellectual property, and some
of the most respected minds in this dynamic field.
There are three strategic components to Arrowhead's
-- The Commercialization Program:
Arrowhead forms or acquires majority-owned subsidiary
companies pursuing products based on nanotechnology
in high-growth technology markets.
-- The Research Program: Arrowhead
funds nanoscience research at universities in exchange
for exclusive rights to license the technology.
-- The Patent Toolbox: Arrowhead
acquires, licenses, and sublicenses intellectual property
in nanotechnology. To date, Arrowhead has licensed
Arrowhead Research operates
four majority-owned subsidiary companies:
-- Aonex Technologies, Inc.,
developing and commercializing proprietary semiconductor
-- Insert Therapeutics, Inc.,
developing and commercializing a proprietary nanoscale
drug delivery system.
-- Nanotechnica, Inc., developing
a variety of proprietary nanoscale devices and systems,
including laboratory on a chip.
-- Calando, Inc. is developing
nanostructures for delivery and therapeutic use of
Arrowhead is funding three
research and development efforts in nanotechnology
at the California Institute of Technology.
Safe Harbor Statement under
the Private Securities Litigation Reform Act of 1995:
Arrowhead Research Corporation
R. Bruce Stewart, 626-792-5549